Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TG Therapeutics's Other Operating Expense for the
three
months ended in Mar. 2026 was €-0.0 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.0 Mil.
TG Therapeutics's quarterly Other Operating Expense
declined
from Sep. 2025 (€0.0 Mil) to Dec. 2025 (€-0.0 Mil) and
declined
from Dec. 2025 (€-0.0 Mil) to Mar. 2026 (€-0.0 Mil).
TG Therapeutics's annual Other Operating Expense
declined
from Dec. 2023 (€0.0 Mil) to Dec. 2024 (€0.0 Mil) and
declined
from Dec. 2024 (€0.0 Mil) to Dec. 2025 (€-0.0 Mil).
TG Therapeutics Other Operating Expense Related Terms
TG Therapeutics Other Operating Expense Historical Data
* Premium members only.
The historical data trend for TG Therapeutics's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €-0.0 Mil mean?
TG Therapeutics (FRA:NKB2) has a Other Operating Expense of €-0.0 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on TG Therapeutics and its competitors.
Is TG Therapeutics' Other Operating Expense too high?
TG Therapeutics' current Other Operating Expense is €-0.0 Mil. Overall, TG Therapeutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Other Operating Expense compare to PTGX and CRNX?
TG Therapeutics' Other Operating Expense of €-0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current Other Operating Expense is €-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Fairly Valued. The stock's GF Value™ is €49.79, compared to a current price of €46.20 — trading 7.2% below its estimated fair value. The current Other Operating Expense is €-0.0 Mil. TG Therapeutics' overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Other Operating Expense is €-0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TG Therapeutics (FRA:NKB2) Overvalued in 2026?
Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued.
The current stock price of €46.20 is trading 7.2% below its estimated GF Value™ of €49.79.
GuruFocus considers TG Therapeutics to be Fairly Valued.
Key valuation signals for FRA:NKB2:
Other Operating Expense: €-0.0 Mil
GF Value™: €49.79 vs. price of €46.20 (7.2% below fair value)
No single metric tells the full story. See the FRA:NKB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
80GF Score
Get the complete analysis for FRA:NKB2
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NKB2 has been successfully added to your 
